Yanina Grant-Huerta Sells 2,414 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 2,414 shares of Atara Biotherapeutics stock in a transaction on Monday, May 18th. The shares were sold at an average price of $9.13, for a total value of $22,039.82. Following the completion of the transaction, the chief accounting officer directly owned 49,636 shares of the company’s stock, valued at $453,176.68. This represents a 4.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Price Performance

Shares of NASDAQ ATRA opened at $9.34 on Friday. The stock has a market capitalization of $84.15 million, a PE ratio of -13.94 and a beta of -0.30. The business has a fifty day moving average price of $6.04 and a two-hundred day moving average price of $8.93. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. On average, equities analysts expect that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after purchasing an additional 12,677 shares in the last quarter. Marshall Wace LLP increased its holdings in Atara Biotherapeutics by 28.4% in the 4th quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock worth $2,689,000 after purchasing an additional 32,836 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Atara Biotherapeutics by 183.5% in the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after purchasing an additional 41,302 shares in the last quarter. Bridgeway Capital Management LLC increased its holdings in Atara Biotherapeutics by 133.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 18,691 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Atara Biotherapeutics by 58.6% in the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 11,104 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics News Summary

Here are the key news stories impacting Atara Biotherapeutics this week:

• Positive Sentiment: Zacks highlighted that Atara Biotherapeutics’ stock has surged over the past month after the FDA outlined a regulatory pathway for tab-cel, reviving hopes for U.S. approval following two prior complete response letters. This is the main bullish driver behind recent momentum. Article Title
• Neutral Sentiment: Several firms, including Rosen Law Firm, Faruqi & Faruqi, Levi & Korsinsky, Pomerantz, Schall, Bronstein, Gewirtz & Grossman, and Bragar Eagel & Squire, issued reminders about a May 22 lead-plaintiff deadline in an already filed securities class action covering investors who bought shares between May 20, 2024 and January 9, 2026. The filings reiterate legal risk but do not add new operational details. Article Title
• Neutral Sentiment: Atara also disclosed insider sales by CEO Anhco Nguyen and CAO Yanina Grant-Huerta, but both transactions were reported as being made to cover tax withholding tied to equity vesting, which typically limits their significance as a negative signal. Article Title

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Freedom Capital raised Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. Finally, Canaccord Genuity Group set a $13.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.